Voltar
Artigo Produção Nacional Revisado por pares
BIBTEX RIS

Results of a Phase II Study of Short-Course Accelerated Radiation Therapy (SHARON) for Multiple Brain Metastases

2013; Lippincott Williams & Wilkins; Volume: 38; Issue: 4 Linguagem: Inglês

10.1097/coc.0b013e3182a0e826

ISSN

1537-453X

Autores

L. Caravatta, Francesco Deodato, M. Ferro, Gabriella Macchia, Mariangela Massaccesi, Savino Cilla, Rosa Tambaro, S. Mignogna, Gilbert D. A. Padula, Michela Musacchio, Mariano Flocco, Giampaolo Cantore, Andrea Scapati, Solomon Bogale, M. Balducci, Vincenzo Valentini, Numa Cellini, A.G. Morganti,

Tópico(s)

Lung Cancer Research Studies

Resumo

To assess the effectiveness of a SHort-course Accelerated RadiatiON therapy (SHARON) in the treatment of patients with multiple brain metastases.A phase II clinical trial was designed. Eligibility criteria included patients with at least 3 brain metastases or metastatic disease in >3 organ systems, and Eastern Cooperative Oncology Group performance status of ≤3. Fifty patients were treated with whole brain radiotherapy at 18 Gy (4.5 Gy per fraction) in 2 days with a twice daily fractionation. The primary endpoint was the assessment of efficacy in terms of overall survival.Characteristics of the 50 enrolled patients were: male/female: 24/26; median age: 65 years (range, 45 to 80 y). Eastern Cooperative Oncology Group performance status was <3 in 42 patients (84%). Nineteen patients (38%) were considered to have recursive partitioning analysis class 3 disease. Grade 1-2 acute neurological (46%) and skin (24%) toxicities were recorded. Three patients (6%) experienced neurological grade 3 acute toxicity. With a median follow-up time of 6 months (range, 1 to 18 mo) 2 skin grade 1 late toxicities has been observed. Seventeen of 27 symptomatic patients showed an improvement or resolution of baseline symptoms (overall palliative response rate: 63.0%; 95% confidence interval, 36.6%-82.4%).Two-month overall survival was 86% (median survival time=7 mo).Short-course accelerated whole brain radiotherapy of 18 Gy in twice daily fractions for 2 consecutive days is tolerated and effective in terms of symptom relief and median survival time. These results justify a phase III comparison against the standard-of-care in this patient population (30 Gy in 10 fractions).

Referência(s)